♎️ 🔮 retweeted
$OCGN Ocugen Price Target Announced at $10.00/Share by Oppenheimer
benzinga.com/quote/OCGN/anal…
♎️ 🔮 retweeted
#OCUGEN $OCGN..... $15 price target sounds good, but very conservative imo.
♎️ 🔮 retweeted
$OCGN if you think holding in the red is difficult, try holding in the green. Patience for patients.
♎️ 🔮 retweeted
$OCGN Ocugen’s Strategic Advancements and Promising Prospects Justify Buy Rating
tipranks.com/news/ratings/oc…
♎️ 🔮 retweeted
Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea $OCGN tinyurl.com/2y8q86u8
♎️ 🔮 retweeted
$ocgn Here’s some added context: the standard of care for GA (Apellis’ Syfovre & Iveric’s Izervay) showed 14–18% slowing of lesion growth after monthly injections for 12 months vs sham.
Ocu410 just showed a 80% relative reduction at 6 months, from a single administration vs the endless injections required with Syfovre/Izervay.
For perspective, Izervay was Iveric’s only late stage asset when Astellas acquired them for $5.9B.
Do what you will with that info. As for me? I’m gonna get rich 🤑 💸 🏦 🍻
I’m still confused about what Jeremiah did to Huda that was so heinous. They keep talking about it, someone explain it to me like I’m a child because this is BS #LoveIdlandUSA
2
235
♎️ 🔮 retweeted
$OCGN - Ocugen
🔹Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST
🔹Modifier Gene Therapy Candidate for Stargardt Disease
🔹Phase 1 trial showed 48% slower lesion growth and statistically significant visual improvement
FDA clearance accelerates development timeline by 2-3 years
👆 6.1% PreM/ $1.22
♎️ 🔮 retweeted
$ocgn you ever watch a stock go from spare change to double digits, then triple?
Keep your eyes on Ocugen over the next 3 years, you’ll see. The next big pharma is making its debut. 🍻
globenewswire.com/news-relea…
♎️ 🔮 retweeted
$OCGN We've all been saying "This is just the beginning"... Now their CEO just said it 😜 Love it! Can't wait to see what comes next in the long line of dominos on the road to curing blindness #PatienceForPatients
♎️ 🔮 retweeted
$OCGN Another major catalyst about to strike , that would be 3 in 30 days , CEO IS DOING WONDERS. Love it !!
♎️ 🔮 retweeted
📢 The new FDA has bold priorities!
@DrMakaryFDA outlines a forward-facing vision in @JAMA_current that tackles chronic disease, accelerates cures, and puts gold-standard science & common sense at the heart of everything.
Read the full article: jamanetwork.com/journals/jam…
♎️ 🔮 retweeted
$OCGN PR: Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene
Therapy for the Treatment of Stargardt Disease ir.ocugen.com/node/13791/pdf
♎️ 🔮 retweeted
$ocgn CEO recently called the Ocu410 data a major inflection point for the company, noting strong global interest in our Ocu400 series and confirming that Big Pharma partnership offers are being reviewed in Q1 this year.
Deals like this typically take 1–3 months to finalize once agreed upon, putting the timeline awfully close to this PR. Combine that with unusually high dark pool volume, a borrow rate spiking to 60%+, last weeks price rally in a red market, and it’s clear some big money is positioning in anticipation of something…
Shorts can talk a big game, but they need to, not like they plan to hold long term with borrow fees at 60%+ and major PR’s on deck. 😜 🍻 🐂
teapaw.org/nattacop/status/184708…
$ocgn good Ocu410 data would imply a lot more than a potential cure for a disease effecting millions.
It solidifies the deal Ocugen has to offer, and a partnership that includes territorial rights for Ocu400 the next cure for RP and Ocu410 a potential cure for Geographic Atrophy(GA) that’s phase three ready, is a deal worth well over a billion dollars.
A phase 1 gene therapy for GA sold for $1.5b in 2021 but failed its phase 2 September 2023.
🔜💸 🏦👽
♎️ 🔮 retweeted
$ocgn doesn’t get better than this. 🍻
Today, Ocugen announced a positive 2-year safety and efficacy update for the Phase 1/2 OCU400 clinical trial. This data highlights the unique therapeutic potential of OCU400. Read the full press release here: bit.ly/40wLSUg #GeneTherapy #BlindnessDiseases #RP






























